Beyond renoprotective impact; ameliorative effects of metformin on malignancies
| Autor: | Mohammadreza Khosravi, Mohammad Davoodi, Sara Bahadoram, Nozar Dorestan, Maedeh Barahman, Mohammad Bahadoram |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
medicine.medical_specialty endocrine system diseases Colorectal cancer lcsh:RC870-923 Prostate cancer Breast cancer Internal medicine Diabetes mellitus medicine Pharmacology (medical) Lung cancer business.industry lcsh:RM1-950 nutritional and metabolic diseases Cancer lcsh:Diseases of the genitourinary system. Urology medicine.disease Metformin Colon cancer lcsh:Therapeutics. Pharmacology Nephrology Liver cancer business medicine.drug |
| Zdroj: | Journal of Nephropharmacology, Vol 7, Iss 2, Pp 50-54 (2018) |
| ISSN: | 2345-4202 |
| Popis: | Diabetes therapies were associated with either a reduced or increased risk of cancer. There are continuous discussions about a possible protective action of metformin. In fact, metformin, a commonly consumed anti-diabetic medication has an ameliorative impact on some cancers by direct (preventing cell growth and apoptosis) and indirect (increasing insulin sensitivity) effects. Observational reports have suggested which metformin reduces the incidence of few common cancers. In general, metformin is an extensively recommended anti-diabetic medication with a recognized ability coupled with a satisfactory and safety profile and inexpensive. This review article considers reduction and protective abilities of metformin on cancers especially prostate, liver, breast, lung, and colon cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|